Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib Neoadjuvant Therapy for Locally Advanced Primary Salivary Gland Adenocarcinoma
NCT05013515Unknown
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Aug 2021
- Primary completion
- Sep 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of surufatinib in Salivary gland adenocarcinoma (SGAC), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Objective Response Rate at 12 months. Status: unknown.
02
Drugs
surufatinib
03
Conditions
Salivary gland adenocarcinoma (SGAC)
Beyond the preview
Go deeper on NCT05013515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013515.